Commentary: Using the entire toolbox for improved survival in anaplastic lymphoma kinase-positive non-small cell lung cancer: The next normal?
J Thorac Cardiovasc Surg
.
2022 Feb;163(2):452-453.
doi: 10.1016/j.jtcvs.2020.10.042.
Epub 2020 Oct 17.
Authors
Staci Beamer
1
,
Jonathan D'Cunha
2
Affiliations
1
Department of Cardiothoracic Surgery, Mayo Clinic Arizona, Phoenix, Ariz.
2
Department of Cardiothoracic Surgery, Mayo Clinic Arizona, Phoenix, Ariz. Electronic address: DCunha.Jonathan@mayo.edu.
PMID:
33162170
DOI:
10.1016/j.jtcvs.2020.10.042
No abstract available
Publication types
Editorial
Comment
MeSH terms
Anaplastic Lymphoma Kinase / genetics
Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms*
Protein Kinase Inhibitors
Substances
Protein Kinase Inhibitors
Anaplastic Lymphoma Kinase